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Alzheimer’s disease is a severe chronic neurodegenerative disorder characterized by beta-amyloid plaques, tau pathology,
cerebrovascular damage, inﬂammation, reactive gliosis, and cell death of cholinergic neurons. The aim of the present study is
to test whether the glia-derived molecule S100b can counteract neurodegeneration of cholinergic neurons after oxygen-glucose
deprivation (OGD) in organotypic brain slices of basal nucleus of Meynert. Our data showed that 3 days of OGD induced a
marked decrease of cholinergic neurons (60% of control), which could be counteracted by 50 μg/mL recombinant S100b. The
eﬀect was dose and time dependent. Application of nerve growth factor or ﬁbroblast growth factor-2 was less protective. C-fos-like
immunoreactivitywasenhanced3hoursafterOGDindicatingmetabolicstress.WeconcludethatS100bisapotentneuroprotective
factor for cholinergic neurons during ischemic events.
1.Introduction
Alzheimer’s disease (AD) is characterized by beta-amyloid
plaque depositions, tau pathology, inﬂammation, cere-
brovascular damage, and cell death of cholinergic neurons.
The lack of cortical acetylcholine directly correlates with
cognitive impairment. Loss of function and degeneration
of cholinergic neurons in the basal forebrain has been
a central theme in AD research, leading to cholinergic
neuroprotection strategies for therapy [1]. Loss of trophic
support by target neurons in the cortex has been considered
as one mechanism for cholinergic degeneration [1]. Fur-
thermore, cholinergic neurons show pathological changes
such as accumulation of neuroﬁbrillary tangles and axonal
abnormalities early during aging and AD [2–4]. Changes of
the basal forebrain are already found in the presymptomatic
phase of AD using neuroimaging [5, 6]. Exogenous trophic
factors can support cholinergic neurons in vitro and in vivo
and replacement strategies have been under consideration
fortreatingAD.Nervegrowthfactor(NGF)issofarthemost
potent trophic factor to protect cholinergic neurons against
neurodegeneration [7]. However, other trophic molecules
are also of considerable interest, such as, for example, S100b.
S100b is a calcium-binding protein predominantly pro-
duced in astrocytes [8], but also oligodendrocytes have been
shown to express the protein [9]. S100b is released from glial
cells and reaches surrounding neurons on which it exerts
trophic functions under physiological conditions [8, 10, 11].
Neuroprotection against glutamate toxicity has been shown
in neuronal cell culture models [12]. S100b also activates
microglial cells and stimulates iNOS or IL1β via the NF-
kappaB pathway [13, 14]. RAGE (receptor for advanced
glycosylation end products
(AGE)) has also been linked to cellular activation by
S100b [15]. S100b has been also linked to AD, because
astrocytes are strongly activated in AD and in the brain
and tissue levels of S100b are increased [16]. It was gen-
erally thought that the astroglial response serves protective
functions, including the increased production of trophic
factors and uptake of beta-amyloid peptides, but negative2 Cardiovascular Psychiatry and Neurology
aspects of astrocytic activation have also been uncovered
[17]. It was postulated that excessive production of S100b
could cause damage to neurons in the brain of AD patients
[16, 18]. In fact, overexpression of human S100b exacerbated
brain damage after ischemia-hypoxia [19, 20], and arundic
acid ameliorated ischemic damage by preventing astrocytic
overproduction of S100b [21]. Taken together, at low
(nanomolar) concentrations S100b exerts trophic functions
on neurons, whereas at high (micromolar) concentrations
the protein stimulates cytokine production which in turn
may trigger apoptosis [10].
It has been suggested that chronic neurovascular damage
and moderate ischemia-hypoxia (silent strokes) may play a
role in the progression of AD [22]. Moderate ischemia and
hypoxia can stimulate astrocytes [23]. In the brain aﬄicted
by AD, loss of trophic support coexists with hypoxic condi-
tions stimulating glial cells, resulting in complex interactions
that may involve S100b. Ischemic damage of neurons pro-
vokes reactions of astrocytes whereby immunohistochemical
labeling for S100b is detected in reactive astrocytes and in
damaged neurons [24].
The aim of the present study is to explore the role
of S100b on cholinergic neurons in our well established
organotypic brain slice culture model in which cholinergic
basal nucleus of Meynert (nBM) neurons are provided with
NGF for two weeks. Slices incubated without NGF display
loss of choline acetyltransferase (ChAT) labeling after two
weeks [25] which is an indicator of neurodegeneration.
Oxygen-glucose deprivation (OGD) of slice cultures has
become an established model for “ischemia-like” conditions
[26–28]. In this report, we show that prolonged OGD
induces loss of ChAT signals of 2-week old nBM neurons
and that S100b can protect against the detrimental eﬀects
of OGD. No evidence for a negative eﬀect of S100b itself
was detected. The present study suggests that S100b plays a
protective role for cholinergic neurons undergoing ischemia-
hypoxia stress.
2.MaterialsandMethods
2.1. Organotypic Brain Slices. Cholinergic neurons in organ-
otypic brain slices were cultured as described by us in
detail [25, 29]. Brieﬂy, the basal nucleus of Meynert of
postnatal day 8 (P8) rats was dissected under aseptic
conditions, 400μm slices were cut with a tissue chopper
(McIlwain, USA), and the slices were placed on 30mm
Millicell-CM 0.4μm pore membrane culture plate inserts
(7-8 slices per membrane). Slices were cultured in 6-well
plates at 37◦C and 5% CO2 with 1.2mL/well of slice
medium (50% MEM/HEPES (Gibco), 25% heat-inactivated
horse serum (Gibco/Lifetech, Austria), 25% Hanks’ solu-
tion (Gibco), 2mM NaHCO3 (Merck, Austria), 6.5mg/mL
glucose (Merck), and 2mM glutamine (Merck), pH 7.2)
including 10ng/mL nerve growth factor (NGF) for 2 weeks.
It is well-established that the 400μm brain slices become
thinner during the 2 weeks of incubation and have a
thicknessofapproximately100μmafter2weeks.Sliceswhich
did not ﬂatten were removed from the experiments. For
the experiment the 2-week old slices were cultured for 3
days without NGF and then transferred to diﬀerent media:
( 1 )m e d i u mw i t hn o r m a l3 3 . 2m Mg l u c o s eo r( 2 )m e d i u m
with low (6.15mM) glucose. Recombinant S100b from
bovine brain (Calbiochem) was added to the medium at
concentrations from 0.1–50μg/mL. Alternatively, 10ng/mL
NGF or 2ng/mL ﬁbroblast growth factor-2 (FGF-2) was
added. It has to be noted that slices could not be cultured
in medium without any glucose, because then slices become
shrunken and cannot be evaluated.
2.2. Oxygen-Glucose Deprivation (OGD). Slices in the wells
(with low glucose) were transferred to a Modular Incubator
Hypoxia Chamber (MIC-101, Billups-Rothenberg, Inc., Del
Mar, CA, USA) connected to a ﬂow meter. The chamber
was sealed and a mixture of 95% N2/5% CO2 was ﬂushed
at a ﬂow rate of 25L/min for 5 minutes. The in- and out-
ports of the chamber were closed, and the closed air tight
system was placed at 37◦Ci na ni n c u b a t o rf o r1 ,2 ,o r3
days. Measurements by the manufacturer indicate that the
pO2 reached a nadir of 35mmHg after 6hr. At the end of the
experiment the outlet port was slowly opened, the chamber
opened, and the culture wells taken out and slices ﬁxed for 3
hours with 4% paraformaldehyde at 4◦C. Control slices were
kept at normal 5% CO2/air conditions in the incubator at
37◦C.
2.3. Immunohistochemistry. Immunohistochemistry using
the avidin-biotin technique was performed to detect cholin-
ergic neurons as described [30, 31]. All incubations for
immunohistochemistry were performed free-ﬂoating at 4◦C
for 2 days including 0.1% Triton, which allows good pene-
tration of the antibody into the slices from both sides. Fixed
slices were washed for 30minutes with 0.1% Triton/PBS (T-
PBS) at room temperature and pretreated for 20minutes
with 5% methanol/1% H2O2/PBS. Then the slices were
rinsed three times for 10 minutes with PBS, blocked with
20%horseserum/0.2%BSA/T-PBS,andthenincubatedwith
the primary antibody against ChAT (1:750, Millipore) or
c-fos (1:1000, Santa Cruz) in 0.2% BSA/T-PBS for 2 days
at 4◦C. Slices were washed and incubated with secondary
biotinylatedanti-goat(ChAT)oranti-rabbit(c-fos)antibody
(1:200, Vector Laboratories), for 1hour at room tempera-
ture. After rinsing three times in PBS, slices were incubated
in avidin-biotin complex solution (ABC; Elite Standard PK
6100, Vector Laboratories) for 1hr, then washed three times
in 50mM Tris-buﬀered saline (TBS), and the signal was
detected using 0.5mg/mL 3,3 diaminobenzidine (DAB) in
TBS with 0.003% H2O2 as substrate. Slices were then rinsed
in PBS and mounted on gelatine-coated glass slides.
2.4. Quantitative Analysis and Statistics. All neuronal counts
were based on individual sections and show total number of
neuronsperslices.Thenumberofmicroscopicallydetectable
immunoreactive ChAT
+ neurons was counted in the whole
slice visualized under a 20× objective by an investigator
blinded to the treatment code. Multistatistical analysis was
obtained by one-way ANOVA, followed by a subsequentCardiovascular Psychiatry and Neurology 3
Fisher PLSD posthoc test by comparing controls against the
respective treatments, where P<. 05 represents statistical
signiﬁcance.
3. Results
When brain slices were cultured for 2 weeks in medium with
normal glucose levels containing 10ng/mL NGF, approxi-
mately 140 cholinergic nBM neurons/slice were detectable
(Table 1; Figures 1(a) and 1(c)). This number did not
change when slices were incubated without NGF for further
3d a y s( Table 1). Reduction of glucose to 6mM (glucose
deprivation) did not signiﬁcantly change the number of
cholinergic neurons after 1-2-3 days of incubation (Table 1).
Slices exposed to hypoxia at normal (high) glucose did
not show a reduced number of ChAT
+ neurons after 1-2-
3 days of incubation (Table 1). However, when slices were
incubatedinlowglucoseandhypoxia(oxygen-glucosedepri-
vation, OGD), the number of ChAT
+ neurons signiﬁcantly
decreased to about 70 neurons/slice after 3 days but not after
1 or 2 days of incubation (Table 1; Figure 1(b)).
In order to test whether S100b counteracts degeneration
of cholinergic neurons caused by OGD for 3 days, slices
were incubated with 50µg/mL of S100b during the exposure.
S100b counteracted the decrease of ChAT+ neurons after 3
days of OGD (Table 1). By comparison NGF also counter-
acted loss of ChAT+ n e u r o n sb u tw a sl e s sp o t e n t( Table 1).
FGF-2 only slightly counteracted the OGD eﬀect (Table 1).
Incubation of slices with S100b alone did not exert any toxic
eﬀect on ChAT expression in cholinergic neurons (Table 1).
In order to verify stressful eﬀects of OGD on neurons,
slices were stained for c-fos immunoreactivity at 3 and 24
hoursofOGD(Figures1(d)–1(f)).IncontrolswithoutOGD,
immunohistochemistryshowedveryfewc-fospositivenuclei
(Figure 1(d)). The number and intensity of c-fos positive
nuclei signiﬁcantly (P<. 001) increased at 3 hours of OGD
(Figure 1(e) and 1(f)) and thereafter returned to control
levels at 24 hours of OGD.
4. Discussion
In the present study we show that cholinergic neurons of
the basal nucleus of Meynert undergo neurodegeneration
when exposed during 3 days of oxygen-glucose deprivation
in a slice culture model. This neurodegeneration could be
counteracted by recombinant S100b which is an endogenous
glial protein.
4.1.CholinergicNeuronsinBrainSlices. Thecholinergicneu-
rons of the basal forebrain are a functionally homogeneous
population, localized in the medial septum/diagonal band
of Broca and basal nucleus of Meynert (nBM), provide the
majorcholinergicinnervationtothehippocampus/amygdala
and neocortex, respectively, and play a crucial role in
cognition and memory. In neurodegenerative disorders such
as AD, these neurons are dysfunctional and can further
degenerate in the progression of the disease [32]. To study
the mechanisms involved in neurodegenerative processes,
Table 1: Cholinergic neurons after glucose-oxygen deprivation and
neuroprotection with S100b.
Treatment ChAT
+ neurons p1 p2
Day 0 136 ±17 (14) —
+1d GD 128 ±17 (5) ns
OD 131 ±27 (6) ns
OGD 113 ±22 (6) ns —
OGD + S100b
(50μg/mL) 121 ±34 (3) ns
+2d GD 130 ±21 (5) ns
OD 124 ±21 (8) ns
OGD 110 ±25 (6) ns —
OGD + S100b
(50μg/mL) 138 ±25 (6) ns
+3d (-) 138 ±10 (18) —
S100b (50μg/mL) 139 ±18 (19) ns
GD 122 ±16 (13) ns
OD 135 ±12 (12) ns
OGD 81 ±8 (28) ∗∗∗ —
OGD + S100b
(50μg/mL) 130 ±11 (26) ns ∗∗∗
OGD + S100b
(1μg/mL) 89 ±10 (14) ∗∗ ns
OGD + S100b
(0.1μg/mL) 92 ±12 (14) ∗ ns
OGD + FGF-2
(2ng/mL) 102 ±9 (12) P = .06 ns
OGD + NGF
(10ng/mL) 94 ±12 (18) ∗ ns
Brain slices of the nBM were cultured for 2 weeks with 10ng/mL nerve
growth factor (NGF), then for 3 days without NGF and then treated under
oxygen-glucose deprivation (OGD) with or without S100b or NGF or
ﬁbroblast growth factor-2 (FGF-2) for 1–3 days. Values are given as mean
± SEM (n in parentheses). Statistical analysis was performed by one-way
ANOVA with a subsequent Fisher PLSD posthoc test and compared against
the untreated control (p1) or against OGD (p2) (∗P<. 05; ∗∗P<. 01;
∗∗∗P<. 001; ns not signiﬁcant). GD, glucose deprivation; OD, oxygen
deprivation; OGD, oxygen and glucose deprivation.
as well as neuroprotective strategies, the organotypic brain
slice model has been established [25, 33–37]. Detection of
cholinergic neurons was performed using the immunohisto-
chemical marker for the enzyme ChAT, which is expressed
in the cell bodies and nerve ﬁbers. A decreased number of
ChAT
+ neurons directly correlates with neurodegeneration
of cholinergic neurons. In our brain slice model cholin-
ergic nBM neurons are axotomized and the number of
ChAT
+ n e u r o n si sm a r k e d l yd e c r e a s e dw i t h o u te x o g e n o u s
NGF. Application of recombinant NGF counteracts this
degeneration, displaying a slight neuroprotective eﬀect at
a concentration of >0.1ng/mL NGF and full activity at
>1ng/mLNGF[37]. Thus, our brain slice model may allow
tostudythecholinergicphenotypeorthedegenerationofthe
majority of cholinergic neurons, which is seen by shrunken
neurons and loss of nerve ﬁbers and a decrease of the ChAT
+
immunoreactivity. In order to test whether S100b exerts4 Cardiovascular Psychiatry and Neurology
(a) (b) (c)
(d) (e) (f)
Figure1:Immunohistochemistryforcholinergiccholineacetyltransferase(ChAT)positiveneurons(a)–(c)andc-fosimmunoreactivenuclei
(d)–(f) in organotypic brain slices of the basal nucleus of Meynert. Slices show control stainings before ((a), (c), (d)), or 3 days (ChAT
+,( b ) )
or 3 hours (c-fos+, (e) and (f)) after oxygen-glucose deprivation. Scale bar in A = 300μm ((a), (b), (d), and (e)) and 75μm ((c) and (f)).
toxicity on cholinergic neurons, 2-week slices were exposed
to a relatively high dose of 50μg/mL (2.38μM) of S100b for
3 days, but S100b did not aﬀect the cholinergic neurons in
our slice model. It is unlikely that a toxic eﬀect would have
shown with short exposures of 1 or 2 days.
4.2. Oxygen-Glucose Deprivation as a Model of Ischemia. The
OGD model in slice cultures has been widely used to study
“ischemia-like” conditions [26–28]. Most of the studies have
used a strong and transient insult in slice cultures of the
hippocampustomodeltheselectivevulnerabilitytoischemia
that is observed in vivo after cardiac arrest [26]. Neuronal
damage is typically evaluated by dye-uptake and imaging
techniques to quantify treatment eﬀects [28]. The present
model used a mild and more prolonged OGD impact (i.e.,
1–3 d) to simulate the blood ﬂow disturbances in the brain
aﬄicted by vascular changes in AD. The evaluation was
focused on the cholinergic neurons in the nBM using a
high-resolution approach with neuronal counting. OGD in
slice culture eliminates the inﬂuence of blood ﬂow, which
otherwise is a complex variable in animal models of brain
ischemia. The observation that neurons are more vulnerable
to ischemia (= combined loss of oxygen and glucose) than
t oe i t h e rh y p o g l y c e m i ao rh y p o x i aa l o n eh a sb e e nm a d e
in multiple experimental conditions and probably applies
to the clinical situation as well. One has to recognize that
experimental OGD induces strong reductions but not total
removal of glucose and/or oxygen. Since the slices are a
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after 3 days. We observed reductions of cholinergic neurons
but no widespread cell damage. In the case of glucose
deprivation (GD), endogenous stores are not completely
exhausted within three days and alternative metabolites may
be used. We have data showing that glucose reduction
alone for 2 weeks markedly reduced cholinergic neurons.
Oxygen deprivation (= hypoxia) is tolerated because of
anaerobic glycolysis based on glucose stores which last
for three days. Oxygen deprivation longer than 3 days is
problematic, because the pH markedly decreases due to
lactate production.
It should be noted that vascular networks persist in the
slice culture in the absence of blood ﬂow [35, 38]. The slice
model should provide the opportunity to study reactions
of vascular cells to ischemia-like conditions in the absence
of intraluminal inﬂammatory cells. This is an important
aspect, because endothelial cells can produce potentially
damaging factors for cholinergic neurons [36]. In order
to show that cellular stress is initiated soon after onset
of oxygen-glucose deprivation, we analyzed the prototypic
immediate early gene c-fos, which is upregulated within
minutesinresponsetoastrongstimulus,includingischemia,
and rapidly downregulated in most experimental systems,
evenif thestimulus persists. For this purpose it wassuﬃcient
to show that c-fos was increased at 3hours.
4.3. S100b Protects Cholinergic Neurons. The present ﬁnding
that S100b protected cholinergic neurons in the slice culture
model against OGD supplements previous reports of a pro-
tection of hippocampal neurons from glucose deprivation
[39]. At low concentrations, S100b exerts multiple positive
eﬀects on neurons, including control of protein phospho-
rylation, regulation of energy metabolism and function of
the cytoskeleton [8, 10]. Autocrine eﬀects on astrocytes have
also been described [10]. The role of S100b stimulation of
the RAGE receptor in protection remains to be understood
[10]. While there are reports of damaging eﬀects of S100b
in high concentrations [10], our experimental data do
not suggest a negative inﬂuence on cholinergic neurons in
vitro, at least for 3 days. In our study we tested diﬀerent
concentrations of 0.1–50μg/mL but only the highest dose
of 50μg/mL (=2.38μM) provided protection against oxygen-
g l u c o s ed e p r i v a t i o n .I th a sb e e nr e p o r t e dt h a to x y g e n -
serum-glucose deprivation induces release of S100b in the
nanomolar concentration from astrocytes after 24 hours
[11]. In our slice experiments 0.1μg/mL S100b did not
provide protection. Indeed, we assume that in our model
of oxygen-glucose deprivation, the intrinsic astrocytes do
release S100b but this may be insuﬃcient to provide rescue
of cholinergic neurons in this insult. A 100-fold higher dose
was required to provide protection in our model system
witho xygen-gluc osedepri vationbutitisdiﬃculttocompare
concentrations obtained in diﬀerent experimental systems.
Our organotypic brain slice cultures have a thickness of 100-
150μm by two weeks after explantation and it seems likely
that a higher dose is necessary for diﬀusion deep into slices,
so that concentrations reached at the level of the cell-bodies
several tens of microns deep in the slice may be much lower.
4.4. An Expanded Role for Astrocytes in Alzheimer’s Disease.
Glial cells surrounding the basal forebrain cholinergic neu-
rons are known to provide important paracrine trophic
support, including NGF, FGF-2, epidermal growth factor,
brain-derived neurotrophic factor, and ciliary neurotrophic
factor. S100b could be an additional trophic factor supplied
by local glial cells to cholinergic neurons, and theoretically, a
decline of S100b production could contribute to cholinergic
dysfunction. So far, most studies have focussed on the
activation of astrocytes in the AD brain which are often
related to senile plaques [40]. However, a reduction of glial
function could be part of the complex pathophysiology of
AD and improving glial function should be protective [17].
It is notable that two of the major risk genes for late-onset
AD, that is, APOE and CLU/Clusterin [41], have important
functions in astrocytes [42, 43], and gene variants could
relate to reduced glial functions. Thus, complex interactions
between the primary processes in AD (beta-amyloid plaque
depositions, tau pathology), moderate ischemia-hypoxia,
and genetic variations of glial reactions can be envisaged.
In fact, it has been reported that S100b protects LAN-5
neuroblastomacellsagainstbeta-amyloid-inducedneurotox-
icity at lower nanomolar doses, while S100b was toxic to
LAN-5 cells at micromolar doses [44]. In their study [44]
individual cells were exposed directly to S100b, whereas in
our model the protein had to diﬀuse into the slices. In fact,
neurons or glial cells in isolation on culture dishes do not
have protection from surrounding cells and are exposed to
high levels of radical oxygen species. Our slice model may
incorporate these endogenous protective mechanisms. One
could argue that our model using a tissue explant is closer to
the in vivo situation than cell cultures. Another explanation
is also that the recombinant S100b is derived from the
bovine gene, while we use rat brain slices, and a mismatch in
protein sequence and/or altered dimeric/monomeric forms
may contribute to a lower functional eﬃciency on rat brain
S100b sensitive receptors.
In conclusion the present study shows that 3 days of
oxygen-glucose deprivation induced a marked decrease of
cholinergic neurons, which could be counteracted by S100b.
WeconcludethatS100bisapotentneuroprotectivefactorfor
cholinergic neurons after ischemic events.
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